Comparative Pharmacology
Head-to-head clinical analysis: ICLEVIA versus ICOTYDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ICLEVIA versus ICOTYDE.
ICLEVIA vs ICOTYDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits indoleamine 2,3-dioxygenase 1 (IDO1), thereby blocking tryptophan catabolism and reversing immune suppression in the tumor microenvironment.
ICOTYDE (trifluridine/tipiracil) is a combination of trifluridine, a thymidine-based nucleoside analog that incorporates into DNA and inhibits cell proliferation, and tipiracil, a thymidine phosphorylase inhibitor that increases the systemic exposure of trifluridine by inhibiting its degradation.
No standard dosing available; Iclevia is not a recognized medication.
Intravenous: 1000 mg administered over 90 minutes on days 1 and 15 of a 28-day cycle.
None Documented
None Documented
Terminal elimination half-life is approximately 8-12 hours in patients with normal renal function, allowing for once-daily dosing.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; may be prolonged in renal impairment.
Renal elimination of unchanged drug accounts for approximately 60-70% of the administered dose; fecal elimination accounts for 20-30%, with less than 5% metabolized.
Renal excretion of unchanged drug accounts for approximately 70% of elimination, with biliary/fecal elimination contributing the remaining 30%.
Category C
Category C
LAMA/LABA Combination
ICS/LABA Combination